Study shows strong 1-dose immune response with Pfizer vaccineA single dose of the Pfizer-BioNTech COVID-19 vaccine was immunogenic in 92% of recipients, with no difference in immunogenic response between men and women but a decreasing response among older recipients, researchers from Israel's Bar-Ilan University reported yesterday in Eurosurveillance.The research also showed that, among those with previous evidence of infection with SARS-CoV-2, the virus that causes COVID-19, the immune response to a single dose was significantly stronger.In the study, 514 Israeli healthcare workers received the vaccine and had their antibody levels measured before vaccination and 21 days after the first dose.
Read more on cidrap.umn.edu